Skip to main content
PMC home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 2002 Nov;61(Suppl 2):ii64–ii66. doi: 10.1136/ard.61.suppl_2.ii64

Using estimated yearly progression rates to compare radiographic data across recent randomised controlled trials in rheumatoid arthritis

V Strand, R Landewe, D van der Heijde
PMCID: PMC1766712  PMID: 12379626

Full Text

The Full Text of this article is available as a PDF (149.9 KB).

Figure 1 .

Figure 1

Open in a new tab

US 301 two year cohort (baseline to year 2). Mean/median, interquartile ranges by tertiles of estimated yearly progression at baseline. LEF, leflunomide; MTX, methotrexate.

Figure 2 .

Figure 2

Open in a new tab

MN 302/4 two year cohort (baseline to year 2). Mean/median, interquartile ranges by tertiles of estimated yearly progression at baseline. Percentages represent the distribution of patients in each tertile in the year 2 cohort. LEF, leflunomide; MTX, methotrexate.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bathon J. M., Martin R. W., Fleischmann R. M., Tesser J. R., Schiff M. H., Keystone E. C., Genovese M. C., Wasko M. C., Moreland L. W., Weaver A. L. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med. 2000 Nov 30;343(22):1586–1593. doi: 10.1056/NEJM200011303432201. [DOI] [PubMed] [Google Scholar]
  2. Boers M., COBRA Study Group. Combinatietherapie Bij Reumatoide Artritis Demonstration of response in rheumatoid arthritis patients who are nonresponders according to the American College of Rheumatology 20% criteria: the paradox of beneficial treatment effects in nonresponders in the ATTRACT trial. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy. Arthritis Rheum. 2001 Nov;44(11):2703–2704. doi: 10.1002/1529-0131(200111)44:11<2703::aid-art451>3.0.co;2-e. [DOI] [PubMed] [Google Scholar]
  3. Bresnihan B., Alvaro-Gracia J. M., Cobby M., Doherty M., Domljan Z., Emery P., Nuki G., Pavelka K., Rau R., Rozman B. Treatment of rheumatoid arthritis with recombinant human interleukin-1 receptor antagonist. Arthritis Rheum. 1998 Dec;41(12):2196–2204. doi: 10.1002/1529-0131(199812)41:12<2196::AID-ART15>3.0.CO;2-2. [DOI] [PubMed] [Google Scholar]
  4. Cohen S., Cannon G. W., Schiff M., Weaver A., Fox R., Olsen N., Furst D., Sharp J., Moreland L., Caldwell J. Two-year, blinded, randomized, controlled trial of treatment of active rheumatoid arthritis with leflunomide compared with methotrexate. Utilization of Leflunomide in the Treatment of Rheumatoid Arthritis Trial Investigator Group. Arthritis Rheum. 2001 Sep;44(9):1984–1992. doi: 10.1002/1529-0131(200109)44:9<1984::AID-ART346>3.0.CO;2-B. [DOI] [PubMed] [Google Scholar]
  5. Emery P., Breedveld F. C., Lemmel E. M., Kaltwasser J. P., Dawes P. T., Gömör B., Van Den Bosch F., Nordström D., Bjorneboe O., Dahl R. A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000 Jun;39(6):655–665. doi: 10.1093/rheumatology/39.6.655. [DOI] [PubMed] [Google Scholar]
  6. Genovese Mark C., Bathon Joan M., Martin Richard W., Fleischmann Roy M., Tesser John R., Schiff Michael H., Keystone Edward C., Wasko Mary Chester, Moreland Larry W., Weaver Arthur L. Etanercept versus methotrexate in patients with early rheumatoid arthritis: two-year radiographic and clinical outcomes. Arthritis Rheum. 2002 Jun;46(6):1443–1450. doi: 10.1002/art.10308. [DOI] [PubMed] [Google Scholar]
  7. Jiang Y., Genant H. K., Watt I., Cobby M., Bresnihan B., Aitchison R., McCabe D. A multicenter, double-blind, dose-ranging, randomized, placebo-controlled study of recombinant human interleukin-1 receptor antagonist in patients with rheumatoid arthritis: radiologic progression and correlation of Genant and Larsen scores. Arthritis Rheum. 2000 May;43(5):1001–1009. doi: 10.1002/1529-0131(200005)43:5<1001::AID-ANR7>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  8. Lipsky P. E., van der Heijde D. M., St Clair E. W., Furst D. E., Breedveld F. C., Kalden J. R., Smolen J. S., Weisman M., Emery P., Feldmann M. Infliximab and methotrexate in the treatment of rheumatoid arthritis. Anti-Tumor Necrosis Factor Trial in Rheumatoid Arthritis with Concomitant Therapy Study Group. N Engl J Med. 2000 Nov 30;343(22):1594–1602. doi: 10.1056/NEJM200011303432202. [DOI] [PubMed] [Google Scholar]
  9. Scott D. L., Pugner K., Kaarela K., Doyle D. V., Woolf A., Holmes J., Hieke K. The links between joint damage and disability in rheumatoid arthritis. Rheumatology (Oxford) 2000 Feb;39(2):122–132. doi: 10.1093/rheumatology/39.2.122. [DOI] [PubMed] [Google Scholar]
  10. Scott D. L., Smolen J. S., Kalden J. R., van de Putte L. B., Larsen A., Kvien T. K., Schattenkirchner M., Nash P., Oed C., Loew-Friedrich I. Treatment of active rheumatoid arthritis with leflunomide: two year follow up of a double blind, placebo controlled trial versus sulfasalazine. Ann Rheum Dis. 2001 Oct;60(10):913–923. doi: 10.1136/ard.60.10.913. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Sharp J. T., Lidsky M. D., Collins L. C., Moreland J. Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities. Arthritis Rheum. 1971 Nov-Dec;14(6):706–720. doi: 10.1002/art.1780140605. [DOI] [PubMed] [Google Scholar]
  12. Sharp J. T. Scoring radiographic abnormalities in rheumatoid arthritis. Radiol Clin North Am. 1996 Mar;34(2):233-41, x. [PubMed] [Google Scholar]
  13. Sharp J. T., Strand V., Leung H., Hurley F., Loew-Friedrich I. Treatment with leflunomide slows radiographic progression of rheumatoid arthritis: results from three randomized controlled trials of leflunomide in patients with active rheumatoid arthritis. Leflunomide Rheumatoid Arthritis Investigators Group. Arthritis Rheum. 2000 Mar;43(3):495–505. doi: 10.1002/1529-0131(200003)43:3<495::AID-ANR4>3.0.CO;2-U. [DOI] [PubMed] [Google Scholar]
  14. Sharp J. T., Wolfe F., Corbett M., Isomaki H., Mitchell D. M., Furst D. E., Sibley J., Shipley M. Radiological progression in rheumatoid arthritis: how many patients are required in a treatment trial to test disease modification? Ann Rheum Dis. 1993 May;52(5):332–337. doi: 10.1136/ard.52.5.332. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Smolen J. S., Kalden J. R., Scott D. L., Rozman B., Kvien T. K., Larsen A., Loew-Friedrich I., Oed C., Rosenburg R. Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet. 1999 Jan 23;353(9149):259–266. doi: 10.1016/s0140-6736(98)09403-3. [DOI] [PubMed] [Google Scholar]
  16. Strand V., Cohen S., Schiff M., Weaver A., Fleischmann R., Cannon G., Fox R., Moreland L., Olsen N., Furst D. Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Leflunomide Rheumatoid Arthritis Investigators Group. Arch Intern Med. 1999 Nov 22;159(21):2542–2550. doi: 10.1001/archinte.159.21.2542. [DOI] [PubMed] [Google Scholar]
  17. Strand V., Lassere M., van der Heijde D., Johnson K., Boers M. Recent rheumatoid arthritis clinical trials using radiographic endpoints--updated research agenda. J Rheumatol. 2001 Apr;28(4):887–889. [PubMed] [Google Scholar]
  18. Wolfe F., Strand V. Radiography of rheumatoid arthritis in the time of increasing drug effectiveness. Curr Rheumatol Rep. 2001 Feb;3(1):46–52. doi: 10.1007/s11926-001-0050-1. [DOI] [PubMed] [Google Scholar]
  19. van der Heijde D. M., van Leeuwen M. A., van Riel P. L., van de Putte L. B. Radiographic progression on radiographs of hands and feet during the first 3 years of rheumatoid arthritis measured according to Sharp's method (van der Heijde modification). J Rheumatol. 1995 Sep;22(9):1792–1796. [PubMed] [Google Scholar]
  20. van der Heijde D. How to read radiographs according to the Sharp/van der Heijde method. J Rheumatol. 1999 Mar;26(3):743–745. [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

[Web only figure]
annrheumd_61_suppl-2_ii64__index.html (866B, html)
annrheumd_61_-2_ii64__figw1.gif (3.8KB, gif)

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES